The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Millennium
Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).
 
Robert W. Chen
Honoraria - Genentech/Roche; Merck; Millennium; Seagen
Consulting or Advisory Role - Genentech/Roche; Merck; Seagen
Speakers' Bureau - Genentech/Roche; Millennium; Seagen
Research Funding - Millennium (Inst); Pharmacyclics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Merck; Seagen
 
Stephen M. Ansell
Honoraria - Research to Practice; WebMD
Research Funding - Affimed Therapeutics (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Regeneron (Inst); Seagen (Inst)
 
Andrea Gallamini
Consulting or Advisory Role - Millennium
Speakers' Bureau - Millennium
 
Joseph M. Connors
Research Funding - Amgen; Bayer; Bristol-Myers Squibb; Cephalon; Genentech; Janssen; Lilly; Merck; Millennium; NanoString Technologies; Proacta; Roche Canada; Seagen
 
Kerry J. Savage
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Seagen; Takeda
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Merck; Novartis; Seagen; Servier
Research Funding - Roche (Inst)
 
Graham P. Collins
Honoraria - Gilead Sciences; Millennium; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Celleron Therapeutics; Gilead Sciences; Millennium; MSD; Pfizer; Roche
Speakers' Bureau - Gilead Sciences; Millennium; Roche
Research Funding - Amgen (Inst); Celgene; MSD (Inst)
Travel, Accommodations, Expenses - Millennium; Napp Pharmaceuticals; Roche
 
Andrew Grigg
Honoraria - Bristol-Myers Squibb; Millennium; Roche
 
Anna M. Sureda
No Relationships to Disclose
 
Nilanjan Ghosh
Consulting or Advisory Role - Janssen; Juno Therapeutics; Kite, a Gilead company; Spectrum Pharmaceuticals
Speakers' Bureau - Abbvie; Celgene; Gilead Sciences; Janssen Oncology
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Janssen (Inst); Juno Therapeutics (Inst); Pharmacyclics (Inst); Seagen (Inst); TG Therapeutics (Inst)
 
Tatyana Feldman
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb; Kite, a Gilead company; Pharmacyclics/Janssen; Seagen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Seagen
Speakers' Bureau - Abbvie; Kite, a Gilead company; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Portola Pharmaceuticals (Inst); Seagen (Inst); Viracta Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Kite, a Gilead company; Pharmacyclics; Seagen
 
Alexander Fosså
Honoraria - Millennium; MSD
Consulting or Advisory Role - Millennium
Research Funding - Millennium
 
Evren Ozdemir
No Relationships to Disclose
 
Fritz Offner
No Relationships to Disclose
 
Gerald Engley
Employment - Seagen
 
Keenan Fenton
Employment - Seagen
 
Shih-Yuan Lee
Employment - Millennium
 
Hina Jolin
Employment - Millennium
 
Ashish Gautam
No Relationships to Disclose
 
Martin Hutchings
Consulting or Advisory Role - Bayer; Celgene; Genentech; Millennium
Research Funding - Celgene (Inst); Genentech (Inst); Janssen-Cilag (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; Millennium